Scholarlink

<p>Based on the results of the ASPIRE trial, the KRd regimen (carfilzomib, lenalidomide and dexamethasone) has been approved in Italy for relapsed/refractory multiple myeloma (RRMM) patients since 2016. The published KRd schedule indicates this combination for 18 cycles, followed by continuous Rd until progression. However, in Italy, there are no limits to the number of KRd cycles, fully refunded based on negotiation with the Italian regulatory agency, and in some centers this combination has been used continuously, beyond the 18th cycle (continuous KRd, cKRd). To evaluate and compare safety and efficacy of both continuous and fixed KRd, we retrospectively collected real-world data from 356 patients treated in 20 EMN (European Myeloma Network) Italian centers from October 2016 to September 2023 and we patients treated with cKRd with those treated with the ASPIRE schedule. After a median follow-up of 48.59 months (CI 27.24–61.24), the overall response rate (ORR) of the entire series was 83% with 35% of complete responses(CR). The mPFS was 23.1 months (CI 20.11–28.62) and mOS was 62.85 months (CI 53.75–70.34), longer than the mOS of the ASPIRE study (48.3 months). The landmark analysis of the cKRd population shows non-significant benefit both in terms of PFS and OS compared to patients where the administration of KRd was stopped at the 18th cycle as in the ASPIRE trial, to note, in the cKRd group patients had a more aggressive disease based on ISS and R-ISS stage. Therefore, although we did not observe additional toxicities, our retrospective analysis, while confirming the validity of the KRd regimen in RRMM, does not indicate any general advantage in keeping the administration of carfilzomib beyond the ASPIRE schedule. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月7日

查看全文
  • Concetta Conticello,
  • Vittorio Del Fabro,
  • Alessandra Romano,
  • Anna Mele,
  • Roberto Mina,
  • Sara Bringhen,
  • Alessandra Orofino,
  • Elisabetta Antonioli,
  • Stefano Pulini,
  • Lorenzo De Paoli,
  • Tommaso Za,
  • Emilia Cotzia,
  • Federica Elia,
  • Andrea Casson,
  • Eleonora Prete,
  • Stefania Citiso,
  • Carmine Liberatore,
  • Gloria Margiotta-Casaluci,
  • Francesca Fazio,
  • Sonia Morè,
  • Irene Attucci,
  • Fabrizio Accardi,
  • Velia Bongarzoni,
  • Silvia Mangiacavalli,
  • Elena Rossi,
  • Donato Mannina,
  • Bruno Garibaldi,
  • Rita Rizzi,
  • Monica Di Cecca,
  • Bernardino Rossini,
  • Giuseppina Uccello,
  • Cirino Botta,
  • Dario Leotta,
  • Donatella Vincelli,
  • Massimo Gentile,
  • Alfonso Piciocchi,
  • Giovanni Marsili,
  • Francesca Patriarca,
  • Renato Zambello,
  • Pellegrino Musto,
  • Mario Boccadoro,
  • Massimo Offidani,
  • Maria Teresa Petrucci,
  • Francesco Di Raimondo

摘要

Based on the results of the ASPIRE trial, the KRd regimen (carfilzomib, lenalidomide and dexamethasone) has been approved in Italy for relapsed/refractory multiple myeloma (RRMM) patients since 2016. The published KRd schedule indicates this combination for 18 cycles, followed by continuous Rd until progression. However, in Italy, there are no limits to the number of KRd cycles, fully refunded based on negotiation with the Italian regulatory agency, and in some centers this combination has been used continuously, beyond the 18th cycle (continuous KRd, cKRd). To evaluate and compare safety and efficacy of both continuous and fixed KRd, we retrospectively collected real-world data from 356 patients treated in 20 EMN (European Myeloma Network) Italian centers from October 2016 to September 2023 and we patients treated with cKRd with those treated with the ASPIRE schedule. After a median follow-up of 48.59 months (CI 27.24–61.24), the overall response rate (ORR) of the entire series was 83% with 35% of complete responses(CR). The mPFS was 23.1 months (CI 20.11–28.62) and mOS was 62.85 months (CI 53.75–70.34), longer than the mOS of the ASPIRE study (48.3 months). The landmark analysis of the cKRd population shows non-significant benefit both in terms of PFS and OS compared to patients where the administration of KRd was stopped at the 18th cycle as in the ASPIRE trial, to note, in the cKRd group patients had a more aggressive disease based on ISS and R-ISS stage. Therefore, although we did not observe additional toxicities, our retrospective analysis, while confirming the validity of the KRd regimen in RRMM, does not indicate any general advantage in keeping the administration of carfilzomib beyond the ASPIRE schedule.